Zeqin Lian

666 citations
22 papers · 527 indexed · h-index 14
Topics
Adipokines, Inflammation, and Metabolic Diseases (9 papers)Adipose Tissue and Metabolism (6 papers)Metabolism, Diabetes, and Cancer (4 papers)
Partner nations
ChinaUnited States

In The Last Decade

Zeqin Lian

21 papers receiving 524 citations

Peers

Zeqin Lian
Comparison fields: 5 of 91
  • Molecular Biology 211
  • Pharmacology 124
  • Epidemiology 118
  • Physiology 90
  • Immunology 68
Replace Hong‐Bo Xiao with:
Hong‐Bo Xiao China
Jai‐Eun Kim South Korea
Hun Hwan Kim South Korea
Antonio Ramón Martín Spain
Gyeong Eun Hong South Korea
Sungwon Lee South Korea
Kyung Hwan Jegal South Korea
Yongning Sun China
Liang Feng China
Wen-Huang Peng Taiwan
Zeqin Lian relative to Hong‐Bo Xiao China Hong‐Bo Xiao's profile →
Citations per field
00.5×1.5×2.1×
Hong‐Bo Xiao · 1×
Citations per year

Countries citing papers authored by Zeqin Lian

Since Specialization
Citations

This map shows the geographic impact of Zeqin Lian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeqin Lian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeqin Lian more than expected).

Fields of papers citing papers by Zeqin Lian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeqin Lian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeqin Lian. The network helps show where Zeqin Lian may publish in the future.

Co-authorship network of co-authors of Zeqin Lian

This figure shows the co-authorship network connecting the top 25 collaborators of Zeqin Lian. A scholar is included among the top collaborators of Zeqin Lian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeqin Lian. Zeqin Lian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 7
4 16
5 4
6 2
7 28
8 5
9 18
10 25
11 38
12 14
13 90
14 20
15 22
16 38
17 21
18
Lipid-lowering effect of cordycepin (3'-deoxyadenosine) from Cordyceps militaris on hyperlipidemic hamsters and rats.
26
19 105
20 29

About Zeqin Lian

Zeqin Lian is a scholar working on Epidemiology, Endocrine and Autonomic Systems and Immunology, having authored 22 papers that have together received 527 indexed citations. Recurring topics across this work include Adipokines, Inflammation, and Metabolic Diseases (9 papers), Adipose Tissue and Metabolism (6 papers) and Metabolism, Diabetes, and Cancer (4 papers). The work is most often cited by research in Complementary and alternative medicine (64 citations), Pharmacology (124 citations) and Pharmacology (59 citations). Zeqin Lian has collaborated with scholars based in China and United States. Frequent co-authors include Haibo Zhu, Jian Gao, Xueying Peng, Huaizhu Wu, Zijian Li, Nana Zhang, Chongming Wu, Peng Guo, Haibo Zhu and Ping Zhu. Their work appears in journals such as PLoS ONE, Cell Metabolism and Diabetes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026